![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Wednesday, January 27, 2021 9:31:38 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
January 27 2021 - 08:39AM
Edgar (US Regulatory)
Alert
Print
Share On Facebook
Free Writing Prospectus dated January 26, 2021
Filed pursuant to Rule 433
Relating to the Preliminary Prospectus Supplement dated
January 26, 2021
Registration Statements Nos. 333-236200 and 333-252451
TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million
RESEARCH TRIANGLE PARK, N.C. — (BUSINESS WIRE)—Jan. 26, 2021— TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 23,083,333 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 3,462,499 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 29, 2021, subject to customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The gross proceeds of the offering are expected to be approximately $69.25 million, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of the underwriter’s option to purchase additional shares. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital and funding research and development activities.
The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-236200) that was filed with the U.S. Securities and Exchange Commission (“SEC”) on January 31, 2020 and declared effective on February 10, 2020 and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) and became automatically effective on January 26, 2021. The shares of common stock may be offered only by means of a prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering, when filed, may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by email at placements@hcwco.com or by phone at (646) 975-6996.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
https://ih.advfn.com/stock-market/AMEX/transenterix-TRXC/stock-news/84180786/free-writing-prospectus-filing-under-securities
Recent ASXC News
- Kuehn Law Encourages ICCH, DO, ASXC, and DPSI Investors to Contact Law Firm • PR Newswire (US) • 06/11/2024 12:04:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 08:19:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 12:50:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:50:23 PM
- Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ • GlobeNewswire Inc. • 06/07/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:33:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 10:55:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:51:25 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024 • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:55:00 AM
- Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 04/29/2024 10:55:00 AM
- Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG • GlobeNewswire Inc. • 04/03/2024 12:45:00 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023 • GlobeNewswire Inc. • 03/21/2024 08:05:00 PM
- U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines • IH Market News • 03/21/2024 11:26:38 AM
- Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 10:55:00 AM
- Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference • GlobeNewswire Inc. • 02/28/2024 11:55:00 AM
- Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals • GlobeNewswire Inc. • 02/27/2024 11:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:01:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:00:04 AM
- Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 01/16/2024 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:21 AM
- Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update • GlobeNewswire Inc. • 01/08/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:45:21 PM
- Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System • GlobeNewswire Inc. • 01/04/2024 09:15:00 PM
- Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 11:55:00 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM